PulseSight Therapeutics SAS

PulseSight is a clinical-stage biotech company committed to developing disruptive non-viral vectorized therapies with minimally invasive delivery technology for the treatment of retinal disease with a focus on age-related macular degeneration (AMD) including wet AMD and geographic atrophy (GA) secondary to dry AMD.

 

Already clinically validated for its safety, PulseSight’s technology platform delivers DNA plasmids encoding therapeutic proteins into the ciliary muscle using an electro-transfection system. The ciliary muscle cells act as biofactories, expressing therapeutic proteins that reach the retina with high distribution, providing a safe and long-acting treatment for major eye diseases.

 

Based in Paris, France, PulseSight’s investors are Pureos Bioventures, ND Capital and Korea Investment Partners (KIP).

For more information visit www.PulseSightTherapeutics.com

Watch the video of the technology here: https://pulsesight.com/technology/

Follow us on LinkedIn – https://www.linkedin.com/company/pulsesight-therapeutics/